SPONSORED 🔽

Legendary Trader Tom Busby is a friend of ours and he is getting ready for the big reveal of his new project: Everyday Income.

But what Tom is about to share with you today has worked on over 100 private signals with a remarkable 72.5% success rate…

And over the last few weeks, Tom and his team have been able to fine tune the strategy to make it even better.

Click here to login.

Disclosure: The profits and performance shown are not typical, we make no future earnings claims, and you may lose money. From 1/1/23 through 8/14/23 the win rate is 72.5%, based on a $2,500 starting stake the average return is $258 and the average winner is $735.

Hello Stock Traders,

Moderna just pulled off a magic trick that sent its stock soaring like a rocket fueled by mRNA. Turns out, their joint venture with Merck on a melanoma vaccine isn’t just about zapping tumors – it might be the golden ticket to reviving Moderna’s fortunes after a two-year slump.

Imagine this: you’re a nasty melanoma hiding out in someone’s skin. You think you’re all smug and comfy, but then BAM! This personalized vaccine, tailor-made to your genetic fingerprint, shows up like a Terminator sent from the future. And guess what? This ain’t your grandpa’s chemotherapy. This is cutting-edge science, slicing and dicing your evil plan.

So, what did these brainiacs do? They took a bunch of melanoma patients, gave them this vaccine along with Merck’s trusty drug Keytruda, and then watched what happened. Three years later, the results were like fireworks on the Fourth of July: patients who got the combo were 49% less likely to see their cancer come back or shuffle off this mortal coil compared to the solo Keytruda crew. And get this – their risk of the whole cancer-spreading-death-dealing thing dropped by a whopping 62%.

Now, I’m not a doctor (though I do play one in my dreams), but these numbers sound pretty darn impressive. Even better, they’re an upgrade from last year’s results, proving this vaccine isn’t some one-hit wonder. Moderna’s CEO, Stephane Bancel, is already talking about fast-tracking this bad boy to approval by 2025, which has analysts doing their victory dance.

But here’s the thing: Moderna isn’t exactly rolling in dough these days. Their cash cow, the COVID vaccine, has seen better days. And with biotech stocks generally feeling as exciting as watching paint dry, investors haven’t exactly been lining up to shower Moderna with love.

That’s where this melanoma marvel comes in. It’s not just a potential cure for cancer, it’s a beacon of hope for Moderna’s future. Imagine a world where they’re not just the “COVID guys,” but the pioneers of personalized cancer vaccines. Talk about a game-changer!

Of course, there’s still a long road ahead. Phase 3 trials take time, and even with an accelerated approval, it won’t be an overnight success. But for the first time in a while, there’s a genuine buzz around Moderna that isn’t fueled by booster shots and variant headlines. This is about science, innovation, and the potential to rewrite the playbook on cancer treatment.

So, will this vaccine be the cure for Moderna’s stock woes? Only time will tell. But one thing’s for sure: this ain’t just another boring biotech story. This is a David-vs-Goliath tale of personalized medicine taking on one of the deadliest diseases known to man. And you know what? I’m rooting for David. I mean, who doesn’t love a good underdog story, especially when it involves kicking cancer’s butt?

So here’s to Moderna, to Merck, and to the brave scientists who are pushing the boundaries of what’s possible. May this melanoma vaccine be the first chapter in a much bigger story, one where personalized medicine becomes the norm, not the exception. And who knows, maybe it’ll even give Moderna’s stock the shot in the arm it needs to reclaim its biotech throne. 

–James

Up next: Defying expectations, the S&P 500 has soared 8% since the Fed’s rate hikes began, fueled by cooling inflation, economic growth, and optimism for future rate cuts.

SPONSORED 🔽

Politicians Loading Up on One U.S. Energy Stock 

Senator Ted Cruz, Bill Haggerty of Tennessee, Congressmen David Price, Patrick Fallon, Brian Babin, August Pfluger, Tom Malinowski, Pete Sessions… Both the GOP and the Dems are loading up on one stock.

Why? That’s the most interesting part.

Remember that sinking feeling when the Fed started cranking up interest rates last spring? Stocks looked like they were bracing for a faceplant, right? Well, here’s a plot twist: the S&P 500 has actually jumped 8% since then, soaring like a bird with rocket boosters strapped to its tail. Talk about defying gravity!

So, what gives? Why is the market doing the Macarena while everyone else is juggling inflation and rising debt payments? Buckle up, folks, because we’re diving into the financial jungle to untangle this mystery.

First, let’s rewind. The Fed hiked rates to tackle inflation, that fire-breathing beast that was roasting everyone’s wallets. They hoped to cool things down by making borrowing more expensive, like cranking down the thermostat in a sauna. But everyone expected the stock market to take a big chill in the process.

Here’s the thing, though: inflation might be a grumpy dragon, but it’s also a bit of a shape-shifter. It recently shed its most fearsome form, dropping below 4%, and that seems to have given the market a shot of sunshine. Investors, those ever-optimistic souls, might be betting that the price-gouging monster is tamed for good.

But wait, there’s more! Remember how everyone predicted a recession would be the sequel to this inflation drama? Well, the US economy surprised everyone by doing a victory lap in the third quarter, growing like a well-watered sunflower. Maybe a recession is just a rumor lurking in the shadows, not the main act.

And then there’s the Fed, our central bank friends. After their rate-hike marathon, they’re hinting at a possible chill-out session next year, maybe even reducing rates three times. That’s like promising ice cream after a plate of healthy greens – investors are digging it.

Now, Ben Inker, a financial whiz from the land of smart investments, says there’s even more to the story. He points out that inflation, while annoying, actually adds some plumpness to companies’ value. Think of it like a rising tide lifting all boats (as long as they aren’t leaky yachts). And with the economy blooming, companies themselves can blossom, bumping up their worth and, by extension, their stock prices.

So, there you have it. Investors might be betting on a future where inflation chills, recessions stay on the sidelines, and interest rates become the new happy hour specials. Maybe they’re a little too optimistic, but hey, who doesn’t want to believe in a happy ending?

Of course, this whole situation is like a tightrope walk over a pit of uncertainty. Things could still change, inflation could roar back, the economy could stumble, and the Fed’s promises could evaporate like cotton candy in the rain. But for now, the market’s doing its own victory dance, defying gravity and leaving analysts scratching their heads with a mix of awe and amusement.

And to all the investors out there, remember: even though the market’s currently doing the tango, keep your eyes peeled for a potential change in rhythm. This financial party might end sooner than you think, so dance responsibly and have a contingency plan if the music stops!

Disclaimer:

Trading foreign exchange, stocks, options, or futures on margin carries a high level of risk, and may not be suitable for all investors. Before deciding to trade, you should carefully consider your objectives, financial situation, needs and level of experience.

This newsletter provides general information that does not take into account your objectives, financial situation or needs. The content of this newsletter or our website must not be construed as personal advice. COE Media is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation.

The possibility exists that you could sustain a loss in excess of your deposited funds and therefore, you should not speculate with capital that you cannot afford to lose. You should be aware of all the risks associated with trading on margin. You should seek advice from an independent financial advisor.

Any past performance presented is not necessarily indicative of future success.

Always do your own research and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.

Advertising Disclosure: This email contains paid advertisements and we have been paid in some fashion to send this advertisment to our readers.

If you do not wish to receive this email, then we apologize for the inconvenience. You can immediately discontinue receiving this email by clicking on the unsubscribe link and you will no longer receive this email.  If you have any questions, please send an email with your questions to [email protected]

We strongly urge you to read our full disclaimer here.

COE MEDIA.    1126 S Federal Hwy
Unit #827    Fort Lauderdale, FL 33316 

Unsubscribe 

Privacy Policy